Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;19(10):2491-2496.
doi: 10.1111/jocd.13637. Epub 2020 Aug 9.

Antibody-induced botulinum toxin treatment failure: A review and novel management approach

Yuttana Srinoulprasert  1 , Rungsima Wanitphakdeedecha  2
Affiliations
Review

Antibody-induced botulinum toxin treatment failure: A review and novel management approach

Yuttana Srinoulprasert et al. J Cosmet Dermatol. 2020 Oct.

Abstract

Background: Botulinum neurotoxin A (BoNT/A) has been used for cosmetic indications for many decades. Consumption of BoNT/A usage has been markedly increased for a few years. Even new formulations of BoNT/A to decrease immunogenicity have been released, repeated treatment to maintain efficacy outcome is inevitable and could finally provoke immune response. In the past, prevalence of botulinum treatment failure (BTF) in cosmetic indication was rare leading to less medical concern. Current decade, case reports on BTF, especially antibody-induced botulinum toxin treatment failure (ABTF), have been increasingly revealed and risk factors associated with ABTF have been intensively studied.

Aims: In this article, we will review antibody-induced botulinum toxin treatment failure (ABTF), risk-associated ABTF, prevalence and recent case reports of ABTF, and new approach to deal with ABTF.

Methods: Literature search was conducted using PubMed. The relevant literatures published between January 2000 and May 2020 concerning BTF and ABTF including investigation for ABTF were included and analyzed.

Results: Possible causes of BTF were summarized. ABTF could be a tip of iceberg of BTF, its prevalence, and currently, 10-year case reports of ABTF were published evidence. Risk factors and investigation methods for ABTF were also summarized. Based on previous studies and our experience, novel approach to management of ABTF was described.

Conclusion: Effective management of BTF is to explore causes of treatment failure. Antibodies against BoNT/A complex could be one of many possibilities. Laboratory in vitro tests could be alternative tools to decrease adverse effect and rebooting immune responses in BTF patients.

Keywords: ELISA; antibody-induced botulinum toxin treatment failure; botulinum toxin.

PubMed Disclaimer

References

REFERENCES

    1. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 1989;84(2):353-355.
    1. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46(1):26-29.
    1. Borodic G, Pearce LB, Johnson E. Antibodies to botulinum toxin. Ophthalmology. 1994;101(7):1158-1159.
    1. Bellows S, Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019;11(9):491. https://doi.org/10.3390/toxins11090491
    1. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-1360.

Substances

LinkOut - more resources